At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
A bipartisan, bicameral group of lawmakers is calling on the Federal Trade Commission (FTC) to vote in favor of releasing an interim staff report on pharmacy benefit managers (PBM). Sens.
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
The FTC released a 60-page report Tuesday targeting the biggest three pharmacy benefit managers, claiming the companies hiked ...
“The FTC staff’s second interim report finds that ... CEO of 46booklyn — said he’s glad not to be the only one working to expose PBM practices. He said he launched 46brooklyn in 2018 ...
Cigna's Evernorth Health Services said on Wednesday its actions will enhance transparency about the company's negotiations.
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through ...
A report from the Federal Trade Commission (FTC) has determined that pharmacy benefit managers (PBMs) are linked to significant cost increases for cancer, HIV, and other critical specialty drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback